Richardson K, Keam SP, Zhu JJ, Meyran D, D’Souza C, Macdonald S, Campbell K, Robbins M, Bezman NA, Todd K, Quach H, Ritchie DS, Harrison SJ, Prince HM, Trapani JA, Jenkins MR, Beavis PA, Darcy PK, Neeson PJ. The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells. haematol [Internet]. 2023Jan.1 [cited 2024Apr.18];108(1):83-7. Available from: https://haematologica.org/article/view/haematol.2021.279930